Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir

MLA

Belén Valenzuela, et al. “Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.” The AAPS Journal, vol. 21, no. 1, July 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e4922aae8412d40d6b74dff28ce44845&authtype=sso&custid=ns315887.

APA

Belén Valenzuela, Oliver Ackaert, Thomas N. Kakuda, Elodie Valade, Juan Jose Perez-Ruixo, Sivi Ouwerkerk-Mahadevan, Matthew W. McClure, & Christopher Westland. (2018). Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. The AAPS Journal, 21(1).

Chicago

Belén Valenzuela, Oliver Ackaert, Thomas N. Kakuda, Elodie Valade, Juan Jose Perez-Ruixo, Sivi Ouwerkerk-Mahadevan, Matthew W. McClure, and Christopher Westland. 2018. “Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.” The AAPS Journal 21 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e4922aae8412d40d6b74dff28ce44845&authtype=sso&custid=ns315887.